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OBJECTIVES: To compare the safety and immunogenicity of a
new human serum albumin (HSA)-free formulation of interferon
(IFN) beta-1a (Rebif New Formulation; RNF) with historical
Rebif data. RNF was developed through an extensive research
program to maximize treatment beneﬁt and patient outcomes by
improving injection tolerability and reducing neutralizing anti-
bodies (NAbs). METHODS: This 48-week analysis of a 96-week
phase IIIb multicenter single-arm open-label study (25,632) com-
pared RNF (44 mcg/0.5 mL, self-injected subcutaneously three-
times weekly [tiw]) with historical Rebif® 44 mcg tiw data
(EVIDENCE study) in patients with relapsing multiple sclerosis
(18–60 years; EDSS < 6.0). Safety analyses included eight pre-
speciﬁed adverse event (AE) groups of interest, including injec-
tion-site reactions (ISR) and ﬂu-like symptoms (FLS; includes
“inﬂuenza-like illness” or ≥2 other FLS terms within 48-hours).
NAb titers ≥20 NU/mL at last assessment up to week 48 were
considered NAb+; “persistent NAbs” was deﬁned as NAb+ at
24 and 48 weeks. RESULTS: At week 48, 227/260 patients
(87.3%) remained on treatment. Compared with historical data,
incidence of pre-speciﬁed AEs in the RNF study was markedly
lower for ISR (29.6% versus 83.8%; a three-fold reduction), and
similar or lower for cytopenia (9.6% versus 11.8%), depression
and suicidal ideation (5.8% versus 19.8%), hepatic disorders
(13.1% versus 16.8%), skin rashes (5.4% versus 12.1%),
thyroid disorders (2.3% versus 5.0%) and hypersensitivity reac-
tions (5.4% versus 3.2%). As expected with an HSA-free for-
mulation, incidence of FLS was higher with RNF (70.8% versus
48.1%) and most events were mild/moderate in severity. Com-
pared with historical data, a markedly smaller proportion of
RNF patients had persistent NAbs (2.5% [95%CI: 1.0–5.4]
versus 14.3% [95%CI: 10.7–18.6]) or NAbs at week 48 (13.9%
[95%CI: 9.9–18.7] versus 24.4% [95%CI: 19.9–29.4]). 50% of
NAb+ titers were low (below 200 NU/mL). CONCLUSION:
These data suggest that RNF has better overall safety and lower
immunogenic potential than Rebif®.
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OBJECTIVES: Natalizumab was recently introduced to the U.S.
market for the treatment of relapsing multiple sclerosis (MS). A
model was designed to determine the budgetary impact of 
utilization of natalizumab from a managed care perspective.
METHODS: The model inputs were drug acquisition costs, costs
of drug administration and monitoring, costs of treating relapses,
anticipated reduction in relapse rates after 2 years of therapy,
and estimated market utilization of natalizumab. Outcomes
included per member per month (PMPM) and 2-year overall
costs, including costs of relapses, in a hypothetical health plan
of 1 million members. These were calculated using total phar-
macy and medical costs of each therapy. The budgetary impact
of an estimated 10% shift in utilization of current disease-mod-
ifying therapies (DMTs) to natalizumab was determined by cal-
culating the difference between baseline and adjusted market
values. Utilization of DMTs was based upon market share dis-
tribution prior to the launch of natalizumab and adjusted by
10%: from 40% to 36% for intramuscular interferon (IFN)β-
1a, from 14% to 12.6% for IFNβ-1b, from 30% to 27% for
glatiramer acetate, and from 16% to 14.4% for subcutaneous
IFNβ-1a. RESULTS: If natalizumab captured 10% of the DMT
market for relapsing MS, there would be a $1,369,194 increase
in annual costs to the hypothetical health plan (baseline annual
cost = $25,960,384 versus adjusted annual cost = $27,329,578).
This equates to an increase in PMPM costs of $0.11 (baseline
cost = $2.16 versus adjusted cost = $2.28). Pharmacy costs con-
tributed most to the total cost of therapy in both the current and
adjusted market scenarios. Addition of natalizumab as a treat-
ment option resulted in a savings for total annual cost of relapses
to the plan of $162,347 or $0.01 on a PMPM basis. CON-
CLUSION: Natalizumab will likely result in a minimal increase
in health plan PMPM costs.
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OBJECTIVES: To determine the pattern of headache-related
resource utilization in a sample of managed care plan members
before and after initiation of topiramate (TPM). METHODS:
The HealthCore Database provided pharmacy and medical
claims data. Patients were required to have at least one phar-
macy claim for topiramate between 1/1/00 and 11/30/05, and at
least 12 units dispensed of any combination of migraine-speciﬁc
acute therapy (triptan, ergotamine, or ergotamine combo) during
the 6-month period preceding a ﬁrst pharmacy claim for TPM
(the index date). Headache-related inpatient and outpatient
resource uses were compared: pre-index vs post-index period 1
(PIP1; months 1 through 6) and pre-index vs post-index period
2 (PIP2; months 7 through 12). Statistical analyses included
McNemar’s and Wilcoxon signed-rank tests. RESULTS: A total
of 3246 patients met the inclusion criteria. The mean ± SD age
was 44 ± 10 years; 88% were female. The mean ± SD TPM dose
was 106 ± 75 mg, and mean days on therapy were 144 days.
Compared to pre-index period, use of abortive agents signiﬁ-
cantly decreased during PIP1 (13%, p < 0.0001) and PIP2 (25%,
P < 0.0001). Percentage of patients using triptans and ergota-
mine combinations was signiﬁcantly reduced (p < 0.0001) from
pre-index (85% and 22%) to PIP1 (75% and 11%) and PIP2
(67% and 8%). Use of outpatient resources did not change sig-
niﬁcantly during PIP1, but decreased 33% during PIP2 for TPM
patients. Diagnostic procedures (eg, CT scans and MRIs)
decreased 48% during PIP1 and 74% during PIP2. ER visits
decreased 7% during PIP1 and 27% during PIP2. Total cost was
$2092 per patient in the pre-period, $2089 in PIP1 and $1765
in PIP2. CONCLUSION: TPM was associated with signiﬁcantly
lower health care resource use (ER visits, diagnostics, acute
therapy) in the ﬁrst six months of TPM treatment, with contin-
uing decreases, including physician ofﬁce visits, in months seven
through twelve.
